Diosmin: Flavonoid for Venous Health & Circulation Support

What is Diosmin?

Diosmin is a flavone bioflavonoid naturally occurring in citrus fruits, particularly in the peel and white membranes of oranges and lemons. It belongs to the larger family of polyphenolic plant compounds that have antioxidant and vascular-supportive properties. In supplement form, diosmin is often extracted and concentrated from citrus sources or synthesized, and is frequently combined with its structural precursor, hesperidin.

Chemically, diosmin is a methylated derivative of the flavonoid diosmetin. When consumed, diosmin undergoes modest absorption in the small intestine, with peak plasma levels occurring 2–8 hours post-ingestion. A portion is metabolized by the liver and excreted; gut microbiota also play a role in transforming diosmin and other flavonoids into bioactive metabolites. The bioavailability of diosmin is improved when taken with food, particularly foods containing other polyphenols and fat-soluble compounds.

Diosmin is believed to work primarily by strengthening venous and lymphatic vessel walls, improving their elasticity, reducing capillary permeability, and supporting microcirculation. It may also exert mild anti-inflammatory and antioxidant effects, though the most robust evidence centers on its structural and functional effects on blood vessel integrity and lymphatic drainage.

Evidence-based benefits of Diosmin

Diosmin has been the subject of numerous clinical trials, primarily in Europe, focusing on circulatory and lymphatic conditions. Evidence quality varies by indication; some benefits are supported by multiple randomized controlled trials, while others remain preliminary or observational.

Chronic Venous Insufficiency

Several randomized controlled trials have found that diosmin, often in combination with hesperidin (marketed as Daflon in Europe), reduces symptoms of chronic venous insufficiency such as leg heaviness, pain, swelling, and visible varicose veins. One meta-analysis suggested efficacy for symptom relief over 12–16 weeks of treatment. While these results are encouraging, many studies were conducted in Europe and some had methodological limitations; replication in larger, diverse populations would strengthen confidence.

Hemorrhoid Symptom Relief

Evidence from multiple clinical trials suggests diosmin (often combined with hesperidin) may reduce bleeding, itching, pain, and swelling associated with hemorrhoids. Some trials showed symptomatic improvement within 3–7 days of treatment, though benefits were more pronounced over 3–12 weeks. The proposed mechanism involves improved venous tone and reduced capillary bleeding in hemorrhoidal tissues. However, evidence is most robust for acute symptom relief; long-term prevention data are more limited.

Lymphedema and Lymphatic Dysfunction

Small clinical trials and observational studies suggest diosmin may improve lymphatic drainage and reduce swelling in postoperative lymphedema and chronic lymphatic conditions. Proposed mechanisms include improved lymphatic vessel contractility and reduced fluid leakage. Evidence is preliminary compared to venous insufficiency; more rigorous trials are needed to establish optimal dosing and long-term efficacy.

Microcirculation and Edema

In vitro and animal studies, along with some human trials, suggest diosmin may improve capillary perfusion and reduce edema by stabilizing the endothelial barrier. Clinical trials in conditions such as diabetic microangiopathy show mixed but generally supportive results. Evidence remains exploratory and would benefit from larger, well-controlled human studies in specific patient populations.

Antioxidant and Anti-inflammatory Effects

Laboratory studies demonstrate that diosmin possesses antioxidant properties and may suppress pro-inflammatory pathways. Some clinical trials measured reductions in inflammatory markers; however, these effects have not been robustly linked to clinically meaningful health outcomes in humans. Evidence is preliminary and primarily mechanistic at this stage.

Supplement forms of Diosmin, compared

Diosmin is commercially available as a standalone extract, but is most commonly marketed as part of a standardized combination product containing both diosmin and hesperidin (the European prescription formulation Daflon is a classic example, typically containing 450 mg diosmin + 50 mg hesperidin per tablet). Both forms share similar bioavailability and are typically taken orally; the combination product is generally preferred in clinical trials and may be more effective than diosmin alone, though head-to-head comparative trials are limited.

How much Diosmin should you take?

Clinical trial dosing for diosmin has varied, but typical effective ranges are reported below. Diosmin is not an approved drug in the United States, so no official RDA or UL exists; doses are derived from European clinical practice and research.

• Typical effective dose for chronic venous insufficiency and hemorrhoids: 450–600 mg/day (often as the diosmin + hesperidin combination), divided into 1–3 doses, for 4–12 weeks. Some protocols use up to 1,000 mg/day.
• Short-term acute hemorrhoid symptom relief: 450–600 mg/day for 3–7 days, then continuing at standard dose for 2–4 weeks.
• Lymphedema and edema: 450–600 mg/day for 8–12 weeks, sometimes longer in chronic conditions.
• Maintenance dosing: 300–450 mg/day after symptom resolution, if used long-term.

Diosmin is best absorbed when taken with food or meals containing fat. Some practitioners recommend dividing the daily dose into morning and evening to maintain steady-state plasma levels. There is no evidence of benefit from combining diosmin with other flavonoids (e.g., anthocyanins or quercetin), though such combinations are sometimes marketed; clinical data are lacking. If using diosmin long-term, periodic reassessment with a healthcare provider is advisable to confirm continued benefit and monitor for any delayed side effects.

Safety, side effects, and risks

Diosmin has a generally favorable safety profile based on clinical trials spanning decades of use in Europe. Serious adverse events are rare, and most users tolerate it well. However, long-term safety data in North America are more limited than in Europe, and some special populations warrant caution.

Common Side Effects

Mild gastrointestinal symptoms are the most frequently reported adverse events in clinical trials, including nausea, dyspepsia, abdominal discomfort, and diarrhea. These are typically transient and mild, occurring in roughly 5–15% of trial participants. Headache and dizziness have been reported rarely. Allergic reactions are uncommon but possible in individuals sensitive to citrus or bioflavonoids.

Rare but Serious Concerns

No serious hepatotoxicity, nephrotoxicity, or hematologic abnormalities have been convincingly attributed to diosmin in published trials. However, given its vascular effects and theoretical anti-inflammatory activity, there is a theoretical risk of interaction with anticoagulants or antiplatelet agents (see Interactions below). Rhabdomyolysis or myopathy has not been reported, but is not formally ruled out in long-term use.

Pregnancy and Lactation

Safety in pregnancy and lactation has not been rigorously studied. Most pregnancy registries and clinical guidelines do not recommend diosmin during pregnancy or breastfeeding in the absence of strong clinical need and medical supervision. If you are pregnant, nursing, or planning pregnancy, consult your obstetrician or primary care physician before starting diosmin.

Populations Requiring Caution

Individuals with bleeding disorders, on anticoagulant or antiplatelet therapy, or with a history of spontaneous bleeding should inform their healthcare provider before using diosmin. People with severe liver disease may have reduced ability to metabolize diosmin and should seek medical guidance. Those with a known allergy to citrus fruits should avoid diosmin or use it only under clinical supervision.

Talk to a clinician if you have: active bleeding or a bleeding disorder; are taking warfarin, dabigatran, aspirin, or other anticoagulants; have severe liver or kidney disease; are pregnant or breastfeeding; or have a citrus allergy. Do not use diosmin as a substitute for medical evaluation or treatment of serious circulatory conditions.

Drug and nutrient interactions

• Warfarin and other vitamin K antagonists: Diosmin may have mild antiplatelet and anticoagulant activity. Concurrent use with warfarin could theoretically increase bleeding risk; monitor INR closely and inform your anticoagulation provider if you start diosmin.
• Antiplatelet agents (aspirin, clopidogrel, ticlopidine): Additive antiplatelet effects are theoretically possible; use together only under medical supervision and watch for signs of unusual bruising or bleeding.
• NSAIDs (ibuprofen, naproxen): Diosmin may enhance gastrointestinal irritation when combined with NSAIDs; take together with food and monitor for GI symptoms.
• CYP3A4 and CYP2C substrates: Diosmin may weakly inhibit hepatic cytochrome P450 enzymes; theoretically could increase plasma levels of certain medications (e.g., some statins, calcium channel blockers). Clinical significance is unclear; discuss with your pharmacist or clinician.
• Other bioflavonoids and polyphenol supplements (quercetin, resveratrol, EGCG): Concurrent use is common in herbal practices but has not been well-studied for additive or synergistic effects or safety; avoid excessive polyphenol stacking without professional guidance.
• Antidiabetic medications: Diosmin may have modest glucose-lowering effects; if taking insulin or oral hypoglycemic agents, monitor blood glucose and discuss with your physician before adding diosmin.

For a comprehensive interaction check involving your specific medications and supplements, consult our Interaction Checker Tool.

Who might benefit — and who shouldn't self-supplement without guidance

Frequently asked questions

Related ingredients